Pyxis Oncology, Inc.
PYXS
$1.14
-$0.05-4.20%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | -- | -- | 16.15M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | -- | -- | 16.15M |
| Cost of Revenue | -- | 0.00 | -- | -- | 475.00K |
| Gross Profit | -- | 0.00 | -- | -- | 15.67M |
| SG&A Expenses | 5.36M | 4.37M | 5.31M | 5.37M | 7.45M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.40M | 18.39M | 23.05M | 19.32M | 20.95M |
| Operating Income | -22.40M | -18.39M | -23.05M | -19.32M | -4.81M |
| Income Before Tax | -21.16M | -37.74M | -21.20M | -17.30M | -3.26M |
| Income Tax Expenses | -- | -2.16M | -- | -- | -- |
| Earnings from Continuing Operations | -21.16M | -35.57M | -21.20M | -17.30M | -3.26M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.16M | -35.57M | -21.20M | -17.30M | -3.26M |
| EBIT | -22.40M | -18.39M | -23.05M | -19.32M | -4.81M |
| EBITDA | -21.85M | -17.84M | -22.32M | -18.74M | -3.69M |
| EPS Basic | -0.35 | -0.58 | -0.35 | -0.29 | -0.06 |
| Normalized Basic EPS | -0.22 | -0.17 | -0.22 | -0.18 | -0.04 |
| EPS Diluted | -0.35 | -0.58 | -0.35 | -0.29 | -0.06 |
| Normalized Diluted EPS | -0.22 | -0.17 | -0.22 | -0.18 | -0.04 |
| Average Basic Shares Outstanding | 61.05M | 61.25M | 60.72M | 60.50M | 51.29M |
| Average Diluted Shares Outstanding | 61.05M | 61.25M | 60.72M | 60.50M | 51.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |